Coronary Artery Stenosis Clinical Trial
— FUNCTIONOfficial title:
Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of De Novo Coronary Artery Lesions
This is a prospective, single-center study. The primary purpose of this study is to evaluate the sensitivity and specificity of offline computational ultrasonic flow ratio (UFR) with conventional pressure wire-based fractional flow reserve (FFR) as the standard reference. The study will be conducted in Fuwai Hospital, and a total of 408 patients with coronary vessel diameter stenosis ≥30% and ≤80% are planned to be recruited. Participants who meet the inclusion criteria and do not meet the exclusion criteria will undergo intravascular ultrasound (IVUS) followed by FFR examination. IVUS imaging will be sent to an independent core laboratory for UFR calculation. UFR analyses were performed offline in a blinded fashion without awareness of FFR measurement. Using FFR≤0.80 as the gold standard, the sensitivity and specificity of UFR in the functional significance of coronary artery stenosis will be analyzed.
Status | Not yet recruiting |
Enrollment | 408 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Stable angina pectoris, unstable angina pectoris, or after the acute phase of myocardial infarction - Age =18 years - Written informed consent - Intermediated coronary lesions (diameter stenosis of 30%-80% by visual estimation from coronary angiography) Exclusion Criteria: - Ineligible for diagnostic IVUS or FFR examination - Prior coronary artery bypass grafting of the interrogated vessels - Myocardial infarction within 72 h of coronary angiography - Severe heart failure - Serum creatinine levels >150 umol/L, or glomerular filtration rates <45 ml/kg/1.73 m2 - Allergy to the contrast agent or adenosine - Life expectancy < 2 years - IVUS pullback not covering the entire lesion - Severe myocardial bridge in the interrogated vessel |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
China National Center for Cardiovascular Diseases |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity and specificity of UFR in predicting functionally significant coronary stenosis at the patient level, using FFR as the reference standard | Sensitivity is defined as the proportion of UFR = 0.80 in patients with hemodynamically-significant stenosis as measured by FFR (FFR = 0.80); specificity is defined as the proportion of UFR > 0.80 in patients without hemodynamically-significant stenosis as measured by FFR (FFR > 0.80). | Immediately after the procedure | |
Secondary | Sensitivity and specificity of UFR in predicting functionally significant coronary stenosis at the vessel level, using FFR as the reference standard | Sensitivity is defined as the proportion of UFR = 0.80 in vessels with hemodynamically-significant stenosis as measured by FFR (FFR = 0.80); specificity is defined as the proportion of UFR > 0.80 in vessels without hemodynamically-significant stenosis as measured by FFR (FFR > 0.8). | Immediately after the procedure | |
Secondary | Diagnostic accuracy of UFR in predicting functionally significant coronary stenosis at the patient level, using FFR as the reference standard | Diagnostic accuracy is defined as UFFR (=0.80 or >0.80) to identify hemodynamically-significant coronary stenosis with FFR (=0.8 or >0.8) as the reference standard. | Immediately after the procedure | |
Secondary | The AUC of UFR for coronary stenosis with FFR as the gold standard | AUC is defined as the area under the receiver-operating characteristic curve | Immediately after the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05133843 -
Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis
|
N/A | |
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Completed |
NCT00739466 -
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
|
Phase 2 | |
Completed |
NCT01332591 -
Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy.
|
N/A | |
Completed |
NCT01182428 -
XIENCE V: SPIRIT WOMEN Sub-study
|
Phase 4 | |
Completed |
NCT01310309 -
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Completed |
NCT00531011 -
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Not yet recruiting |
NCT05393882 -
Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
|
||
Recruiting |
NCT06397820 -
Relation Between AI-QCA and Cardiac PET
|
||
Active, not recruiting |
NCT01960504 -
First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
|
N/A | |
Completed |
NCT01721096 -
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
|
||
Active, not recruiting |
NCT01342822 -
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
|
Phase 4 | |
Completed |
NCT01205789 -
EXCEL Clinical Trial (Universal Registry)
|
N/A | |
Recruiting |
NCT05532605 -
Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i
|
N/A | |
Completed |
NCT02066623 -
Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
|
||
Not yet recruiting |
NCT02946320 -
Optimal Predilatation Technique for BVS Implantation
|
Phase 3 | |
Completed |
NCT01136876 -
Kidney Damage in Patients With Moderate Fall in eGFR
|
Phase 4 | |
Completed |
NCT01249027 -
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
|
||
Terminated |
NCT01136915 -
Kidney Damage In Patients With Severe Fall In eGFR
|
Phase 4 |